Aatmaj Healthcare profit rises 53% in H1FY26
Aatmaj Healthcare Limited reported a 53.3% increase in profit for H1FY26 to ₹51.07 lakh, with revenue rising 27.1% to ₹1,081.04 lakh. Total expenses increased to ₹1,056.00 lakh. The board approved the unaudited results, which were reviewed by statutory auditors. IPO proceeds utilisation showed ₹2,926.89 lakh utilised out of ₹3,840.00 lakh, with ₹913.11 lakh kept as FDR for medical equipment.
*this image is generated using AI for illustrative purposes only.
Aatmaj Healthcare Limited reported a 53.3% rise in profit for the half year ended September 30, 2025, to ₹51.07 lakh, compared to ₹33.29 lakh in the year-ago period. Revenue from operations increased 27.1% to ₹1,081.04 lakh from ₹850.80 lakh in the corresponding period of the previous year. The company's total revenue stood at ₹1,125.01 lakh for the period under review.
The Board of Directors approved the standalone unaudited financial results for the half year ended September 30, 2025, at a meeting held on November 13, 2025. The results were reviewed by the Audit Committee and subsequently approved by the board. Bela Mehta and Associates, the statutory auditors, issued a Limited Review Report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Total expenses for the half year increased to ₹1,056.00 lakh from ₹893.71 lakh in the same period last year. Key expense components included employee benefits expense of ₹238.78 lakh, other expenses of ₹557.92 lakh, and finance costs of ₹57.21 lakh. Profit before tax for the period was ₹69.01 lakh, up from ₹32.81 lakh in the previous year.
Financial Performance
| Particulars | Six Months Ended 30.09.2025 (Unaudited) | Six Months Ended 30.09.2024 (Unaudited) |
|---|---|---|
| Revenue from operations | 1,081.04 | 850.80 |
| Total Revenue | 1,125.01 | 926.52 |
| Total Expenses | 1,056.00 | 893.71 |
| Profit Before Tax | 69.01 | 32.81 |
| Profit for the period | 51.07 | 30.64 |
| Basic EPS | 0.23 | 0.14 |
The company's earnings per equity share (basic and diluted) improved to ₹0.23 for the half year ended September 30, 2025, from ₹0.14 in the corresponding previous period. The financial statements were prepared in accordance with Accounting Standard 25 on Interim Financial Reporting.
IPO Proceeds Utilisation
Aatmaj Healthcare disclosed the utilization of its IPO proceeds up to September 30, 2025. The company had raised ₹3,840.00 lakh through its public issue in June 2023. Of this, ₹2,926.89 lakh has been utilised, while ₹913.11 lakh remains unutilised and is kept as a Fixed Deposit Receipt (FDR) with the bank. The unutilised amount is earmarked for the purchase of medical equipment.
| Sr. No. | Object | Amount Disclosed | Actual Utilised | Unutilised Amount |
|---|---|---|---|---|
| 1 | Repayment of debt | 900.00 | 900.00 | - |
| 2 | Working capital | 600.00 | 600.00 | - |
| 3 | Medical equipment | 913.11 | - | 913.11 |
| 4 | Inorganic growth | 620.00 | 620.00 | - |
| 5 | General Corporate Expenses | 496.89 | 496.89 | - |
| 6 | Issue Expenses | 310.00 | 310.00 | - |
| Total | 3,840.00 | 2,926.89 | 913.11 |
Shareholders had approved a variation in the object of the issue via a special resolution passed through remote e-voting in June 2025. This allowed the company to utilise the ₹913.11 lakh for purchasing medical equipment instead of working capital requirements.
Historical Stock Returns for Aatmaj Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.88% | -2.40% | -2.40% | -23.75% | -2.14% | -65.60% |
What specific medical equipment does Aatmaj Healthcare plan to acquire with the remaining ₹913.11 lakh, and how will this impact future service capabilities?
How will the company manage the transition of the unutilized IPO funds from working capital to capital expenditure, and what is the expected timeline for deployment?
Given the 27.1% revenue growth, what strategies is the company employing to control the rising employee benefits and other expenses to sustain profit margins?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
